PMID- 35635135
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220803
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 21
DP  - 2022 Jan-Dec
TI  - Herbal Formula Shenling Baizhu San for Chronic Diarrhea in Adults: A Systematic 
      Review and Meta-analysis.
PG  - 15347354221081214
LID - 10.1177/15347354221081214 [doi]
LID - 15347354221081214
AB  - BACKGROUND: Shenling Baizhu San (SBS), a well-known Chinese medicine herbal 
      formula, has been widely used for treating chronic diarrhea for thousands of 
      years. However, the efficacy and safety of SBS in treating chronic diarrhea have 
      not been fully assessed. OBJECTIVE: This study evaluates the efficacy and safety 
      of the herbal formula SBS in symptomatic relief of chronic diarrhea. METHODS: 
      English and Chinese language databases (PubMed, Cochrane Library, China National 
      Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang 
      Data, and SinoMed electronic databases) were searched through April 2020 for 
      relevant randomized controlled trials (RCTs). The outcomes in these RCTs included 
      stool frequency, stool consistency, patient-reported satisfaction of chronic 
      diarrhea treatment, quality of life and adverse events. Paired reviewers 
      independently extracted data and conducted qualitative and quantitative analyses. 
      The Cochrane revised risk of bias RoB-2 tool was applied to assess the risk of 
      bias for each trial whereas the RevMan 5.3 software was used for outcomes data 
      synthesis and meta-analysis. Mean difference (MD) and the 95% confidence interval 
      (CI) were used to measure continuous data. The dichotomous data were analyzed via 
      the relative risk (RR) with 95% CIs. RESULTS: Fourteen RCTs including 1158 
      participants (54% males) with chronic diarrhea were included. Shenling Baizhu San 
      combined with or without conventional medicine (CM) was associated with greater 
      patient-reported satisfaction than CM alone. There was no increased risk of 
      adverse events (AEs) during treatment. CONCLUSION: Treatment with SBS was 
      associated with significant improvement in patient-reported satisfaction, 
      irrespective of conventional medicine use. Rigorous and powered RCTs with 
      objective outcome measures are needed to confirm the effects of SBS in specific 
      gastrointestinal disease populations with chronic diarrhea symptoms. SYSTEMATIC 
      REVIEW REGISTRATION NUMBER (PROSPERO): CRD42020178073.
FAU - Wang, Hui
AU  - Wang H
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Hou, Yen-Nien
AU  - Hou YN
AUID- ORCID: 0000-0002-7975-5427
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Yang, Mingxiao
AU  - Yang M
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Feng, Ye
AU  - Feng Y
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
AD  - Peking University Cancer Hospital and Institute, Beijing, China.
FAU - Zhang, Yi Lily
AU  - Zhang YL
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Smith, Colleen M
AU  - Smith CM
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Hou, Wei
AU  - Hou W
AD  - Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
FAU - Mao, Jun J
AU  - Mao JJ
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Deng, Gary
AU  - Deng G
AD  - Memorial Sloan Kettering Cancer Center, New York, NY, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (shenling baizhu san)
SB  - IM
MH  - Adult
MH  - Diarrhea/drug therapy
MH  - *Drugs, Chinese Herbal/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - *Medicine, East Asian Traditional
MH  - Phytotherapy/adverse effects
PMC - PMC9158428
OTO - NOTNLM
OT  - Jinryobyakujutsu-san
OT  - Samryungbaekchul-san
OT  - Shenling Baizhu San
OT  - diarrhea
OT  - efficacy and safety
OT  - herbal formula
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Jun J. Mao reports grants from Tibet CheeZheng 
      Tibetan Medicine Co. Ltd. and from Zhongke Health International LLC outside the 
      submitted work. Hui Wang, Yen-Nien Hou, Mingxiao Yang, Ye Feng, Yi Lily Zhang, 
      Colleen M. Smith, Wei Hou, and Gary Deng declare no conflicts of interest.
EDAT- 2022/06/01 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/05/29
CRDT- 2022/05/31 11:47
PHST- 2022/05/31 11:47 [entrez]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/05/29 00:00 [pmc-release]
AID - 10.1177_15347354221081214 [pii]
AID - 10.1177/15347354221081214 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2022 Jan-Dec;21:15347354221081214. doi: 
      10.1177/15347354221081214.